USE OF RETHIONIC ACID DURING PREGNANCY AND LACTATION

Öz

Objective: Retinoic acid and its derivatives are frequently used in various skin diseases, especially acne vulgaris. The use of these active substances, which are known to have teratogenic effects, is frequently encountered during pregnancy and lactation periods. It is especially possible to encounter their use before pregnancy and during the period when pregnancy is the most risky for the healthy development of the baby, including organogenesis. All these data indicate that not enough is known about the teratogenic effects of retinoic acid. In this review, information about teratogenicity, retinoic acid derivatives and their teratogenic effects are discussed. In addition, the literature on the use of topical and systemic retinoic acid during pregnancy and lactation is reviewed and the results of the studies are discussed. Result and Discussion: It is very important to know the teratogenic effects of retinoic acid and its derivatives. There is insufficient data on the systemic and topical use of these compounds during pregnancy and lactation. Increasing evaluations on this subject will allow safer use of retinoic acid derivatives.

Anahtar Kelimeler

• Pregnancy
• lactation
• retinoic acid
• retinoic acid embryopathy

HAMİLELİK VE LAKTASYON DÖNEMİNDE RETİNOİK ASİT KULLANIMI

Öz

Amaç: Retinoik asit ve türevleri başta akne vulgaris olmak üzere çeşitli cilt hastalıklarında sıklıkla kullanılan etken maddelerdir. Teratojenik etkileri olduğu bilinen bu etken maddelerin gebelik ve laktasyon dönemlerinde kullanımına sıklıkla rastlanmaktadır. Özellikle gebelik öncesi ve gebeliğin organogenez de dahil olmak üzere, bebeğin sağlıklı gelişimi için en riskli olduğu dönemde kullanımıyla karşılaşmak mümkündür. Tüm bu veriler retinoik asitin teratojenik etkileri hakkında yeterince bilgi sahibi olunmadığını göstermektedir. Bu derlemede teratojenite hakkında bilgi verilmiş, retinoik asit türevleri ve bunların teratojenik etkilerinden bahsedilmiştir. Ayrıca gebelik ve laktasyon döneminde topikal ve sistemik retinoik asit kullanımıyla ilgili literatürler incelenmiş ve yapılan araştırmaların sonuçlarına değinilmiştir. Sonuç ve Tartışma: Retinoik asit ve türevlerinin teratojenik etkilerinin bilinmesi oldukça önemlidir. Bu bileşiklerin gebelik ve laktasyon döneminde, sistemik ve topical olarak kullanımına ait veriler yetersizdir. Bu konudaki değerlendirmelerin artması retinoik asit türevlerinin daha güvenli kullanımına olanak sağlayacaktır.

Anahtar Kelimeler

• Hamilelik
• laktasyon
• retinoik asit
• retinoik asit embriyopatisi

Kaynakça

1. 1. Kaplan, Y.C., Kelekci, S., Demir, O. (2015). Risk evaluation, risk communication and perinatal evaluation in pregnancies with drug exposure. Nobel Medicus, 11(1), 14-21.
2. 2. Mitchell, A.A., Gilboa, S.M., Werler, M.M., Kelley, K.E., Louik, C., Hernández-Díaz, S., Study, N.B.D.P. (2011). Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. American Journal of Obstetrics and Gynecology, 205(1), 51-e1. [CrossRef]
3. 3. Göker, A., Duman, M.K., Gürpınar, T., Muci, E., Yıldırım, Y., Erköseoğlu, İ., Dikayak Ş., Koyuncu, F.M. (2012). Gebelikte ilaç kullanımı nedeni ile başvuran hastaların değerlendirilmesi. Journal of Clinical Obstetrics & Gynecology, 22(2), 90-94.
4. 4. Yılmaz, İ., Kaplan, Y.C., Karadaş, B., Temiz, T.K., Karaca, Ş. (2015). Gebelikte topikal isotretinoin maruziyeti konjenital malformasyon riskini arttırır mı?. TÜRKDERM-Deri Hastalıkları ve Frengi Arşivi, 49(2), 92-94.
5. 5. Olukman, M., Parlar, A., Orhan, E.C., Erol, A. (2006). Gebelerde ilaç kullanımı: Son bir yıllık deneyim. Uzmanlık Sonrası Eğitim ve Güncel Gelişmeler Dergisi, 3(4), 255-261.
6. 6. Karadaş, B., Can, H., Yılmaz, İ., Demir, Ö., Temiz, T.K., Kaplan, Y.C. (2014). A new era begins in risk communication regarding drug use in pregnancy: Changes in FDA regnancy risk categories. Turkish Journal of Family Practice, 18(4), 195-198. [CrossRef]
7. 7. Çeliker, A., Göçer, M. (2021). Türkiye’de ve Dünyada Teratojenite Bilgi Servislerinin Çalışma Koşulları ve Sağladıkları Hizmetler. Hacettepe University Journal of the Faculty of Pharmacy, 41(2), 102-116. [CrossRef]
8. 8. Miral, M., Beji, N.K. (2017). Gebelikte ilaç kullanımı ve danışmanlık. Sağlık Bilimleri ve Meslekleri Dergisi, 4(2), 142-148.

9. 9. Schaefer, C., Peters, P.W., Miller, R.K. (Eds.). (2015). Drugs during pregnancy and lactation: Treatment options and risk assessment, Academic Press, p.475-478.
10. 10. Faqi A.S., (Ed.) (2017). Developmental and reproductive toxicology, Humana Press, New York, p.30-35.
11. 11. National Research Council, Commission on Life Sciences, Board on Environmental Studies, Committee on Developmental Toxicology. (2000). Scientific Frontiers in Developmental Toxicology and Risk Assessment, National Academy Press, Washington, p. 75-80. [CrossRef]
12. 12. Selcen, D., Seidman, S., Nigro, M.A. (2000). Otocerebral anomalies associated with topical tretinoin use. Brain and Development, 22(4), 218-220. [CrossRef]
13. 13. Karadağ, A.S. (2020). Sistemik izotretinoin. Turkderm-Turkish Archives of Dermatology & Venereology, 54.
14. 14. Panchaud, A., Csajka, C., Merlob, P., Schaefer, C., Berlin, M., De Santis, M., Vial, T., Ieri, A., Malm, H., Eleftheriou, G., Stahl, B., Rousso, P., Winterfeld, U., Rothuizen, L.e., Buclin, T. (2012). Pregnancy outcome following exposure to topical retinoids: A multicenter prospective study. The Journal of Clinical Pharmacology, 52(12), 1844-1851. [CrossRef]
15. 15. Kaplan, Y.C., Ozsarfati, J., Etwel, F., Nickel, C., Nulman, I., Koren, G. (2015). Pregnancy outcomes following first‐trimester exposure to topical retinoids: A systematic review and meta‐analysis. British Journal of Dermatology, 173(5), 1132-1141. [CrossRef]
16. 16. Schaefer, C., Meister, R., Weber-Schoendorfer, C. (2010). Isotretinoin exposure and pregnancy outcome: an observational study of the Berlin Institute for clinical teratology and drug risk assessment in Pregnancy. Archives of Gynecology and Obstetrics, 281, 221-227. [CrossRef]
17. 17. Sarici, D., Akin, M. A., Kurtoglu, S., Uzum, K., Kiraz, A. (2013). Asymmetric crying face in a newborn with isotretinoin embryopathy. Pediatric Dermatology, 30(6), e289-e290. [CrossRef]
18. 18. Alay, M. T., Kalayci, A., Seven, M. (2023). A new perspective on isotretinoin in pregnancy: Pregnancy outcomes, evaluation of complex phenotypes, and importance of teratological counselling. European Journal of Obstetrics and Gynecology and Reproductive Biology, 291, 148-155. [CrossRef]
19. 19. Shirazi, M., Abbariki, E., Pirjani, R., Akhavan, S., Dastgerdy, E. (2015). Congenital microtia in a neonate due to maternal isotretinoin exposure 1 month before pregnancy: Case report. Journal of Obstetrics and Gynecology Research, 41(6), 975-978. [CrossRef]
20. 20. Zomerdijk, I. M., Ruiter, R., Houweling, L. M., Herings, R. M., Sturkenboom, M. C., Straus, S. M., Stricker, B. H. (2014). Isotretinoin exposure during pregnancy: A population-based study in The Netherlands. BMJ Open, 4(11), e005602. [CrossRef]
21. 21. Kim, N. R., Yoon, S. R., Choi, J. S., Ahn, H. K., Lee, S. Y., Hong, D.S., Yun, J. S., Hong, S. Y., Kim, Y. H., Han, J. Y. (2018). Isotretinoin exposure in pregnant women in Korea. Obstetrics and Gynecology Science, 61(6), 649-654. [CrossRef]
22. 22. Bérard, A., Azoulay, L., Koren, G., Blais, L., Perreault, S., Oraichi, D. (2007). Isotretinoin, pregnancies, abortions and birth defects: A population‐based perspective. British Journal of Clinical Pharmacology, 63(2), 196-205. [CrossRef]
23. 23. Autret-Leca, E., Kreft-Jais, C., Elefant, E., Cissoko, H., Darrouzain, F., Grimaldi-Bensouda, L., Attia, S., Jonville-Béra, A. P. (2010). Isotretinoin exposure during pregnancy: assessment of spontaneous reports in France. Drug Safety, 33, 659-665. [CrossRef]
24. 24. Geiger, J.M., Baudin, M., Saurat, J.H. (1994). Teratogenic risk with etretinate and acitretin treatment. Dermatology, 189(2), 109-116. [CrossRef]
25. 25. Kong, Y.L., Tey, H.L. (2013). Treatment of acne vulgaris during pregnancy and lactation. Drugs, 73, 779-787. [CrossRef]
26. 26. Choi, E.J., Kim, N., Kwak, H.S., Han, H.J., Chun, K.C., Kim, Y. A., Koh, J.W., Han, J.Y., Joo, S.H., Lee, J.S., Koren, G. (2021). The rates of major malformations after gestational exposure to isotretinoin: A systematic review and meta-analysis. Obstetrics and Gynecology Science, 64(4), 364-373. [CrossRef]
27. 27. Bozzo, P., Chua-Gocheco, A., Einarson, A. (2011). Safety of skin care products during pregnancy. Canadian Family Physician, 57(6), 665-667.
28. 28. Camera, G., Pregliasco, P. (1992). Ear malformation in baby born to mother using tretinoin cream. The Lancet, 339(8794), 687. [CrossRef]
29. 29. Lipson, A., Collins, F., Webster, W. (1993). Multiple congenital defects associated with maternal use of topical tretinoin. The Lancet, 341(8856), 1352-1353. [CrossRef]
30. 30. Navarre-Belhassen, C., Blanchet, P., Hillaire-Buys, D., Sarda, P., Blayac, J.P. (1998). Multiple congenital malformations associated with topical tretinoin. Annals of Pharmacotherapy, 32(4), 505-506. [CrossRef]
31. 31. Loureiro, K.D., Kao, K.K., Jones, K.L., Alvarado, S., Chavez, C., Dick, L., Felix, R., Johnson, D., Chambers, C.D. (2005). Minor malformations characteristic of the retinoic acid embryopathy and other birth outcomes in children of women exposed to topical tretinoin during early pregnancy. American Journal of Medical Genetics Part A, 136(2), 117-121. [CrossRef]
32. 32. Jick, S.S., Terris, B.Z., Jick, H. (1993). First trimester topical tretinoin and congenital disorders. The Lancet, 341(8854), 1181-1182. [CrossRef]
33. 33. Shapiro, L., Pastuszak, A., Curto, G., Koren, G. (1997). Safety of first-trimester exposure to topical tretinoin: Prospective cohort study. The Lancet, 350(9085), 1143-1144. [CrossRef]
34. 34. Van Hoogdalem, E.J. (1998). Transdermal absorption of topical anti‐acne agents in man; review of clinical pharmacokinetic data. Journal of the European Academy of Dermatology and Venereology, 11, S13-S19. [CrossRef]
35. 35. Autret, E., Berjot, M., Jonville-Béra, A.P., Aubry, M.C., Moraine, C. (1997). Anophthalmia and agenesis of optic chiasma associated with adapalene gel in early pregnancy. The Lancet, 350(9074), 339. [CrossRef]
36. 36. Menter, A. (2000). Pharmacokinetics and safety of tazarotene. Journal of the American Academy of Dermatology, 43(2), S31-S35. [CrossRef]